ICEECE2012 Poster Presentations Endocrine tumours and neoplasia (112 abstracts)
Diagnostic and Prognostic Role of 68GA-Dotatate in Patients with Neuroendocrine Tumors
F. Marciello 1 , A. Faggiano 2 , L. Aloj 2 , C. Caraco 2 , V. Ramundo 1 , V. Marotta 1 , M. Del Prete 1 , A. Carratù 1 , A. Colao 1 & S. La Storia 2
National Cancer Institute “Fondazione G. Pascale”, Naples, Italy.
Octreoscan is currently the gold standard for diagnosis of somatostatin receptor positive NET but it is limited by a lower spatial resolution and physiological uptake noises. DOTATATE is a somatostatin analogue, radiolabelled with 68Ga and adapted for PET imaging.
Aim of this study was to evaluate the diagnostic performance of 68Ga-DOTATATE PET compared to Octreoscan in NET.
Fifty-one patients with NET (40 sporadic, 17 MEN1) of different origin were enrolled. 68Ga-DOTATATE PET was performed in all cases by acquiring whole body studies 40–60 min after the radioligand i.v. injection (74–111 MBq). Octreoscan was also performed in 27/51 patients using injection of Indium-111-DTPA-Phe1-Octreoscanreotide (120–200 MBq). Examinations results were rated considering histology, CT/MR examination and clinical follow-up.
The patient based sensitivity and specificity of PET was 77% and 100%,respectively; the lesion based sensitivity was 64% with a specificity of 85%. Positive and negative predictive values were 100% and 65%, respectively. The sensitivity was ~100% in pancreas and gut, ~75% in lung and thyroid, <50% in stomach. In the subgroup undergone both PET and Octreoscan, the result was concordant in 21 and discordant in 6 cases. The discordant cases were 5 PET positive/Octreoscan negative (3 pancreatic NET, 2 medullary thyroid cancer) and 1 PET negative/Octreoscan positive (atypical lung carcinoid). In PET-positive patients, a significant inverse correlation between SUVmax and Ki67 was recordered (P<0.01). At ROC analysis, SUVmax in patients with progressive disease was ≤17 while it was >17 in patients with stable or responsive disease (P<0.01).
In patients with NET 68Ga-DOTATATE PET shows higher diagnostic performance than Octreoscan and is suggested to predict clinical behaviour of the tumor.
Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.
Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more